… of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung cancer (…
emphasis on understanding the molecular characteristics of tumor specimens. It is now recognized …

… the treatment of non–small cell lung cancer (NSCLC). The use of … development of EGFR
tyrosine kinase inhibitors, the discovery … of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. …

… the kinase inhibitors. However, many gaps remain in understanding the mechanisms of kinase
inhibitors … and non-receptor tyrosine kinase inhibitors and their novel role in lung cancer. …

… tyrosine kinase controlled pathways. Epidermal growth factor receptor tyrosine kinase
inhibitors … in patients with refractory non-small cell lung cancer (NSCLC). Early studies with …

The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …

… cell lung cancers express the Kit receptor tyrosine kinase … , suggesting that inhibitors of Kit
tyrosine kinase activity could … was designed as an Abl tyrosine kinase inhibitor, but also has …

… Approximately 10 to 15% of patients with non-small cell lung cancer have tumors that … to
treatment with the first-generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib or gefitinib. A …

… tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non–small cell lung
cancer … for these cancers. Studies over the last few years have identified two different EGFR …

… non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative
example of the successes in targeting oncogene addiction in cancer and the role of tumor-specific …

… Although the PI3K is undoubtedly important in lung cancers, no specific mutations in … lung
tumors to date (61). We would anticipate further development of PI3K inhibitors in lung cancer …